Compare SGLD & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SGLD | PMVP |
|---|---|---|
| Founded | N/A | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 72.2M |
| IPO Year | 2009 | 2020 |
| Metric | SGLD | PMVP |
|---|---|---|
| Price | $3.21 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 23.1K | ★ 372.5K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $1.02 |
| 52 Week High | $5.45 | $1.91 |
| Indicator | SGLD | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 36.42 | 45.07 |
| Support Level | N/A | $1.24 |
| Resistance Level | $3.70 | $1.40 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 7.71 | 31.58 |
Scorpio Gold Corp is a company that is engaged in mineral exploitation, exploration, and development in the United States. It holds an interest in the Mineral Ridge gold project, which is located in the northwest of the town of Silver Peak and west of Tonopah in Esmeralda County, Nevada. Its other project includes the Goldwedge property, which is located north-northeast of the town of Tonopah within the Manhattan Mining District of south-central Nevada.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.